Bortezomib, Melphalan, Prednisone and Thalidomide followed by maintenance with bortezomib and thalidomide (VMPT-VT) vs Bortezomib, Melphalan and Prednisone (VMP) alone as first line treatment of multiple myeloma: updated follow-up and impact of prognostic factors

Authors
Category Primary study
Year 2011
This article has no abstract
Epistemonikos ID: fa85b10f0f04596bf424a6fefb9ea2ecd73a5206
First added on: Jan 15, 2024